| Schedule of segment and corporate information |
Segment and corporate information in € K | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Care | | Value- | | Care | | Total | | Inter-segment | | | | | | | Delivery | | Based Care | | Enablement | | Segment | | eliminations | | Corporate | | Total | Three months ended September 30, 2026 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 3,279,810 | | 32,816 | | — | | 3,312,626 | | — | | — | | 3,312,626 | Revenue from healthcare products(1) | | 77,123 | | — | | 1,021,529 | | 1,098,652 | | — | | — | | 1,098,652 | Revenue from contracts with customers(1) | | 3,356,933 | | 32,816 | | 1,021,529 | | 4,411,278 | | — | | — | | 4,411,278 | Revenue from insurance contracts(1) | | — | | 503,784 | | — | | 503,784 | | — | | — | | 503,784 | Revenue from lease contracts(1) | | — | | — | | 21,680 | | 21,680 | | — | | — | | 21,680 | Revenue from external customers | | 3,356,933 | | 536,600 | | 1,043,209 | | 4,936,742 | | — | | — | | 4,936,742 | Inter-segment revenue | | 134,997 | | — | | 408,229 | | 543,226 | | (543,226) | | — | | — | Revenue | | 3,491,930 | | 536,600 | | 1,451,438 | | 5,479,968 | | (543,226) | | — | | 4,936,742 | Costs of revenue | | (2,628,106) | | (514,316) | | (1,017,136) | | (4,159,558) | | 496,812 | | 1,377 | | (3,661,369) | Research and development | | — | | — | | (41,398) | | (41,398) | | — | | — | | (41,398) | Operating income (loss) | | 496,903 | | 94 | | (32,430) | | 464,567 | | (46,413) | | (34,065) | | 384,089 | Interest | | | | | | | | | | | | | | (81,459) | Income before income taxes | | | | | | | | | | | | | | 302,630 | Depreciation and amortization | | (234,281) | | (193) | | (117,882) | | (352,356) | | 10,345 | | (13,790) | | (355,801) | Impairment loss | | (714) | | — | | (76,258) | | (76,972) | | — | | (227) | | (77,199) | Income (loss) from equity method investees | | 18,162 | | — | | — | | 18,162 | | — | | — | | 18,162 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 252,614 | | 94 | | 121,121 | | 373,829 | | (53,027) | | 42,851 | | 363,653 | | | | | | | | | | | | | | | | Three months ended September 30, 2025 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 3,211,730 | | 7,939 | | — | | 3,219,669 | | — | | — | | 3,219,669 | Revenue from healthcare products(1)(2) | | 61,511 | | — | | 1,015,683 | | 1,077,194 | | — | | — | | 1,077,194 | Revenue from contracts with customers(1) | | 3,273,241 | | 7,939 | | 1,015,683 | | 4,296,863 | | — | | — | | 4,296,863 | Revenue from insurance contracts(1) | | — | | 567,578 | | — | | 567,578 | | — | | — | | 567,578 | Revenue from lease contracts(1) | | — | | — | | 20,409 | | 20,409 | | — | | — | | 20,409 | Revenue from external customers | | 3,273,241 | | 575,517 | | 1,036,092 | | 4,884,850 | | — | | — | | 4,884,850 | Inter-segment revenue(2) | | 128,465 | | — | | 324,568 | | 453,033 | | (453,033) | | — | | — | Revenue | | 3,401,706 | | 575,517 | | 1,360,660 | | 5,337,883 | | (453,033) | | — | | 4,884,850 | Costs of revenue(2) | | (2,564,750) | | (579,371) | | (942,765) | | (4,086,886) | | 448,587 | | (4,333) | | (3,642,632) | Research and development | | — | | — | | (37,954) | | (37,954) | | — | | 206 | | (37,748) | Operating income (loss)(2) | | 419,474 | | (21,960) | | 86,652 | | 484,166 | | (3,454) | | (4,207) | | 476,505 | Interest | | | | | | | | | | | | | | (73,937) | Income before income taxes | | | | | | | | | | | | | | 402,568 | Depreciation and amortization | | (235,080) | | (1,354) | | (115,569) | | (352,003) | | 10,358 | | (16,569) | | (358,214) | Impairment loss | | (257) | | 21 | | 1,177 | | 941 | | — | | 16 | | 957 | Income (loss) from equity method investees | | 46,672 | | — | | — | | 46,672 | | — | | — | | 46,672 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 143,797 | | 117 | | 131,338 | | 275,252 | | (10,563) | | 14,763 | | 279,452 |
| (1) | These line items are included to comply with requirements under IFRS 8 and IFRS 15 or are provided on a voluntary basis, but not included in the information regularly reviewed by the chief operating decision maker. |
| (2) | For amounts not reclassified related to the shift of the global pharmaceutical business from Care Enablement to Care Delivery, see discussion above. |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Segment and corporate information (continued) | in € K | | | | | | | | | | | | | | | | | | | Value-Based | | Care | | Total | | Inter-segment | | | | | | | Care Delivery | | Care | | Enablement | | Segment | | eliminations | | Corporate | | Total | Nine months ended September 30, 2026 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 9,615,375 | | 93,932 | | — | | 9,709,307 | | — | | — | | 9,709,307 | Revenue from healthcare products(1) | | 254,295 | | — | | 2,911,329 | | 3,165,624 | | — | | — | | 3,165,624 | Revenue from contracts with customers(1) | | 9,869,670 | | 93,932 | | 2,911,329 | | 12,874,931 | | — | | — | | 12,874,931 | Revenue from insurance contracts(1) | | — | | 1,469,175 | | — | | 1,469,175 | | — | | — | | 1,469,175 | Revenue from lease contracts(1) | | — | | — | | 65,349 | | 65,349 | | — | | — | | 65,349 | Revenue from external customers | | 9,869,670 | | 1,563,107 | | 2,976,678 | | 14,409,455 | | — | | — | | 14,409,455 | Inter-segment revenue | | 394,142 | | — | | 1,144,812 | | 1,538,954 | | (1,538,954) | | — | | — | Revenue | | 10,263,812 | | 1,563,107 | | 4,121,490 | | 15,948,409 | | (1,538,954) | | — | | 14,409,455 | Costs of revenue | | (7,769,544) | | (1,461,024) | | (2,849,727) | | (12,080,295) | | 1,431,920 | | 3,767 | | (10,644,608) | Research and development | | — | | — | | (119,337) | | (119,337) | | — | | — | | (119,337) | Operating income (loss) | | 1,203,037 | | 6,386 | | 153,456 | | 1,362,879 | | (107,034) | | (119,706) | | 1,136,139 | Interest | | | | | | | | | | | | | | (242,994) | Income before income taxes | | | | | | | | | | | | | | 893,145 | Depreciation and amortization | | (697,412) | | (1,048) | | (355,708) | | (1,054,168) | | 30,272 | | (42,965) | | (1,066,861) | Impairment loss | | (76,114) | | — | | (80,521) | | (156,635) | | — | | (35,557) | | (192,192) | Income (loss) from equity method investees | | 18,228 | | — | | — | | 18,228 | | — | | — | | 18,228 | Total assets(1) | | 42,136,948 | | 642,093 | | 13,933,863 | | 56,712,904 | | (36,532,670) | | 11,268,977 | | 31,449,211 | thereof investment in equity method investees(1) | | 678,318 | | — | | — | | 678,318 | | — | | — | | 678,318 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 706,814 | | 235 | | 351,498 | | 1,058,547 | | (129,046) | | 102,216 | | 1,031,717 | | | | | | | | | | | | | | | | Nine months ended September 30, 2025 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 9,669,848 | | 51,486 | | — | | 9,721,334 | | — | | — | | 9,721,334 | Revenue from healthcare products(1)(2) | | 193,944 | | — | | 3,020,787 | | 3,214,731 | | — | | — | | 3,214,731 | Revenue from contracts with customers(1) | | 9,863,792 | | 51,486 | | 3,020,787 | | 12,936,065 | | — | | — | | 12,936,065 | Revenue from insurance contracts(1) | | — | | 1,559,217 | | — | | 1,559,217 | | — | | — | | 1,559,217 | Revenue from lease contracts(1) | | — | | — | | 62,735 | | 62,735 | | — | | — | | 62,735 | Revenue from external customers | | 9,863,792 | | 1,610,703 | | 3,083,522 | | 14,558,017 | | — | | — | | 14,558,017 | Inter-segment revenue(2) | | 365,425 | | — | | 991,913 | | 1,357,338 | | (1,357,338) | | — | | — | Revenue | | 10,229,217 | | 1,610,703 | | 4,075,435 | | 15,915,355 | | (1,357,338) | | — | | 14,558,017 | Costs of revenue(2) | | (7,907,680) | | (1,558,685) | | (2,788,045) | | (12,254,410) | | 1,339,193 | | (2,243) | | (10,917,460) | Research and development | | — | | — | | (119,552) | | (119,552) | | — | | 206 | | (119,346) | Operating income (loss)(2) | | 1,085,873 | | (27,553) | | 269,976 | | 1,328,296 | | (17,153) | | (77,965) | | 1,233,178 | Interest | | | | | | | | | | | | | | (229,403) | Income before income taxes | | | | | | | | | | | | | | 1,003,775 | Depreciation and amortization | | (739,402) | | (4,030) | | (339,443) | | (1,082,875) | | 30,600 | | (50,567) | | (1,102,842) | Impairment loss | | (17,336) | | (2,171) | | (4,522) | | (24,029) | | — | | 16 | | (24,013) | Income (loss) from equity method investees | | 139,680 | | — | | — | | 139,680 | | — | | — | | 139,680 | Total assets(1) | | 40,572,794 | | 584,495 | | 14,377,779 | | 55,535,068 | | (35,992,145) | | 11,344,082 | | 30,887,005 | thereof investment in equity method investees(1) | | 751,181 | | — | | — | | 751,181 | | — | | — | | 751,181 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 531,282 | | 315 | | 357,161 | | 888,758 | | (31,342) | | 26,738 | | 884,154 |
| (1) | These line items are included to comply with requirements under IFRS 8 and IFRS 15 or are provided on a voluntary basis, but not included in the information regularly reviewed by the chief operating decision maker. |
| (2) | For amounts not reclassified related to the shift of the global pharmaceutical business from Care Enablement to Care Delivery, see discussion above. |
|